Skip to content

Multimodal Endoscopic Ultrasound in the Evaluation of Indeterminate Upper Gastrointestinal Wall Thickening

Multimodal Endoscopic Ultrasound in the Evaluation of the Nature of Indeterminate Upper Gastrointestinal Wall Thickening

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07407296
Acronym
MM-EUS-UGIWT
Enrollment
43
Registered
2026-02-12
Start date
2026-02-01
Completion date
2028-12-01
Last updated
2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper Gastrointestinal Wall Thickening

Keywords

Endoscopic Ultrasound in Upper Gastrointestinal Wall Thickening

Brief summary

Multimodal endoscopic ultrasound can help to differentiate between benign (non-cancerous) and malignant (cancerous) causes of thickening of the upper digestive tract wall. The main questions this study aims to answer are: How accurate is multimodal endoscopic ultrasound in identifying the cause of upper digestive tract wall thickening? Can using several ultrasound techniques together improve diagnosis when standard tests are unclear? Participants are adults who have upper digestive tract wall thickening seen on scans such as computed tomography (CT) or magnetic resonance imaging (MRI). Participants will: Undergo upper endoscopy followed by endoscopic ultrasound and tissue sample taken during the procedure when needed followed by using biopsy results or clinical follow-up to confirm the final diagnosis This study aims to improve early and accurate diagnosis and help guide proper treatment decisions for people with unexplained upper digestive tract wall thickening.

Detailed description

Upper gastrointestinal wall thickening (UGIT) refers to the abnormal increase in the thickness of the gastrointestinal wall, which can be observed in various clinical conditions, including both benign and malignant diseases (1). Abnormal gastric wall thickening can be caused by a wide range of benign and malignant conditions, and expedient diagnosis is required to commence the appropriate treatment (2, 3). Traditional diagnostic approaches for evaluating UGIT rely primarily on cross-sectional imaging techniques such as contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI). However, these modalities often lack sufficient spatial resolution to accurately characterize the individual layers of the gastrointestinal wall, particularly in cases of subtle mucosal or submucosal disease (4, 5). Esophagogastroduodenoscopy (EGD) allows direct visualization of the mucosal surface and enables tissue sampling through conventional biopsies. Nevertheless, many pathological processes responsible for gastrointestinal wall thickening-such as gastric lymphoma, subepithelial tumors, linitis plastica, and infiltrative scirrhous carcinoma-originate in the deeper layers of the gastrointestinal wall (6). EUS allows clear delineation of the gastrointestinal wall layers and surrounding structures. EUS-guided tissue acquisition using fine-needle biopsy (FNB) allows sampling of submucosal and muscular lesions that are inaccessible to conventional endoscopic biopsies (1).

Interventions

PROCEDUREEndoscopic ultrasound

Multimodal Endoscopic Ultrasound including; conventional B-mode EUS Assessment, doppler evaluation, EUS elastography and Selective EUS-Guided Fine-Needle Biopsy (EUS-FNB)

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Patients with endoscopic or radiological (U/S, CT or MRI) evidence of upper GI wall thickening (esophagus, stomach, or duodenum) and defined based on established radiologic standards. A wall thickness by MSCT \>5 mm in the oesophagus and stomach and \>4 mm in the duodenum in accordance with accepted CT imaging criteria (4, 7). * Written informed consent provided.

Exclusion criteria

* Patient refusal or inability to provide informed consent * Uncorrectable coagulation disorder e.g prothrombin concentration \<60%, INR \>1.5 or platelet count \<50,000/µL that cannot be corrected pre-procedure according to institutional guidelines. * Presence of contraindications for endoscopy/sedation. * Known diagnosis explaining wall thickening prior to EUS.

Design outcomes

Primary

MeasureTime frame
Diagnostic accuracy of multimodal EUSone year

Secondary

MeasureTime frame
EUS imaging patterns associated with various etiologies.one year
Incremental diagnostic value of elastography.one year
Diagnostic yield of EUS-guided tissue acquisition.one year

Countries

Egypt

Contacts

CONTACTTaha Hussein El-sherif
Elsheriftaha74@gmail.com00201114236391
CONTACTAhmed Radwan Riad
Dr.Radwan@aun.edu.eg00201126435001
PRINCIPAL_INVESTIGATORTaha Hussein El-sherif

Assit University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026